---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-009619"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T13:42:14.211097+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Esperion FY24 revenue $332.3M (+186% Y/Y); net loss narrows to $51.7M from $209.2M

## Summary
- FY24 total revenue $332.3M (+186% Y/Y); Q4 revenue $69.1M (+114% Y/Y).
- U.S. net product revenue FY24 $115.7M (+48% Y/Y); Q4 $31.6M (+52% Y/Y).
- FY24 net loss $51.7M ($0.28/sh) vs $209.2M ($2.03/sh) in 2023; Q4 net loss $21.3M ($0.11/sh).
- Announced development of two triple combination products with bempedoic acid.
- Strengthened balance sheet: $304.7M from OMERS royalty deal; repaid $210M convertible debt; cash $144.8M.

## SEC filing metadata
- accession: 0001628280-25-009619
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025009619/0001628280-25-009619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025009619/espr-20250304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-009619
- JSON: https://secwatch.observer/filing/0001628280-25-009619.json
- Plain text: https://secwatch.observer/filing/0001628280-25-009619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.